The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
Oxford Immunotec intends to use the net proceeds from the offering for working capital and general corporate purposes.
Read the rest of entry »
The Department for International Trade Life Sciences Organisation (DIT LSO) and the China Britain Business Council (CBBC) will be hosting a delegation from the Future Health Industry Entrepreneurs Association (FHA) from China on the morning of Tue 5 Sep.
AMSBIO announces the launch of a new Hyaluronic Acid Quantification Kit, based on a highly specific and tightly binding protein to detect and measure Hyaluronic Acid, also known as Hyaluronan or HA.
Oxford BioMedica has sealed a major deal with Novartis to supply the Swiss drug giant with lentiviral vectors used to create cell therapy products, including CTL019 and other undisclosed Chimeric Antigen Receptor T cell (CART) products.
Isansys Lifecare is delighted to announce that we have been chosen to feature in the Government's “GREAT for Imagination” campaign.
Additional space will provide purpose-built research laboratories accommodating around 450 scientists at Immunocore
Leadership in place; Clinical Operations teams growing throughout Europe
BETHESDA, Md., July 6, 2017 /PRNewswire/ -- Precision for Medicine today reported important progress in its global expansion plan. Precision for Medicine, with its oncology research team Precision Oncology, is rapidly expanding its global footprint to better serve clients developing oncology treatments. Investment in executive leadership and operational teams are underway across Europe, providing integrated, full-service clinical trial execution services throughout the continent.
Medical device testing is one of the most complex services offered in the life sciences sector, both for the diversity of the product tested and for the different level of safety or biocompatibility required prior to approval for use in patients.
Immunocore will generate a novel ImmTAC® molecule against the selected target which is relevant in multiple cancers.
A new high throughput assay technology that allows scientists, for the first time, to reliably measure the genotoxic risk of a whole range of environmental agents (including cleaning agents, household products and industrial chemicals as well as cosmetics) to our skin.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, email@example.com, and we will post.